13F Holdings
中文EN

GOSS Gossamer Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1728117 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-58.0%
TTM net income YoY-71.6%
TTM EPS YoY-221.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-361.9%
Net margin-344.8%
FCF margin-383.7%
EBITDA margin-361.1%

Returns

ROE-783.4%
ROA-45.2%
ROIC (approx.)—
Asset turnover0.13x

Leverage & solvency

Liabilities / assets119.1%
Debt / equity—
Current ratio4.40x
Interest coverage-13.28x

Cash quality & payout

Operating cash flow / net income1.11x
Accruals ratio5.1%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$48.47M$114.70M$0$0—
R&D expense$174.09M$138.49M$135.30M$170.92M$170.27M
SG&A expense$37.63M$36.13M$38.45M$47.61M$45.78M
Operating income-$170.73M-$59.92M-$183.76M-$218.59M-$216.12M
Interest expense$10.99M$11.52M$13.51M$13.88M$19.44M
Pretax income-$170.46M-$55.63M-$179.82M-$229.38M-$234.00M
Income tax-$88,000$893,000$0$0—
Net income-$170.37M-$56.53M-$179.82M-$229.38M-$234.00M
EBITDA-$170.70M-$59.09M-$182.15M-$216.76M-$214.38M
EPS (basic)-0.75-0.25-1.18-2.71-3.13
EPS (diluted)-0.75-0.25-1.18-2.71-3.13
Weighted avg. shares (diluted)228.52M226.23M152.62M84.57M74.84M
Balance sheet
Cash & equivalents$37.73M$46.07M$32.11M$111.97M$183.47M
Short-term investments$99.20M$248.44M$264.32M$143.71M$141.81M
Receivables$12.23M$5.34M$0——
Current assets$167.64M$309.89M$306.52M$261.88M$331.78M
PP&E, net$64,000$10,000$1.65M$3.98M$5.32M
Total assets$172.25M$315.29M$311.92M$272.45M$343.66M
Current liabilities$63.44M$45.01M$51.60M$49.23M$39.86M
Short-term debt—$0$11.61M$11.61M$0
Long-term debt—$0$814,000$11.99M$29.08M
Total debt—$0$12.43M$23.60M$29.08M
Total liabilities$295.01M$285.80M$249.15M$260.37M$222.19M
Shareholders' equity-$122.76M$29.49M$62.77M$12.08M$121.46M
Net debt—-$46.07M-$19.68M-$88.37M-$154.39M
Shares outstanding2.92M226.60M225.41M94.42M75.75M
Cash flow statement
Operating cash flow-$171.27M-$3.47M-$159.16M-$187.03M-$188.89M
Capital expenditure$79,000$0$0$410,000$1.55M
Free cash flow-$171.34M-$3.47M-$159.16M-$187.44M-$190.44M
Investing cash flow$156.36M$29.02M-$110.97M-$1.03M-$117.43M
Financing cash flow$6.42M-$11.49M$190.15M$117.09M$3.33M
Depreciation & amortization$24,000$833,000$1.61M$1.83M$1.74M
Stock-based compensation$10.55M$20.62M$28.52M$42.55M$32.01M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.